August 6, 2007
Kyowa Hakko Kogyo announced on July 27 that it has licensed the novel antibody engineering technology COMPLEGENT, which enhances complement-dependent cytotoxicity (CDC) of therapeutic antibodies, to its wholly owned US subsidiary BioWa, following POTELLIGENT, another antibody engineering technology which enhances...read more